JP2021535119A5 - - Google Patents

Info

Publication number
JP2021535119A5
JP2021535119A5 JP2021509906A JP2021509906A JP2021535119A5 JP 2021535119 A5 JP2021535119 A5 JP 2021535119A5 JP 2021509906 A JP2021509906 A JP 2021509906A JP 2021509906 A JP2021509906 A JP 2021509906A JP 2021535119 A5 JP2021535119 A5 JP 2021535119A5
Authority
JP
Japan
Prior art keywords
calcitonin mimetic
amino acid
mimetic according
linking group
calcitonin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021509906A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021535119A (ja
Filing date
Publication date
Priority claimed from GBGB1813678.8A external-priority patent/GB201813678D0/en
Application filed filed Critical
Publication of JP2021535119A publication Critical patent/JP2021535119A/ja
Publication of JP2021535119A5 publication Critical patent/JP2021535119A5/ja
Priority to JP2024193478A priority Critical patent/JP2025023996A/ja
Pending legal-status Critical Current

Links

JP2021509906A 2018-08-22 2019-08-22 アシル化カルシトニン模倣体 Pending JP2021535119A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024193478A JP2025023996A (ja) 2018-08-22 2024-11-05 アシル化カルシトニン模倣体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1813678.8 2018-08-22
GBGB1813678.8A GB201813678D0 (en) 2018-08-22 2018-08-22 Acylated calcitonin mimetics
PCT/EP2019/072533 WO2020039051A1 (en) 2018-08-22 2019-08-22 Acylated calcitonin mimetics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024193478A Division JP2025023996A (ja) 2018-08-22 2024-11-05 アシル化カルシトニン模倣体

Publications (2)

Publication Number Publication Date
JP2021535119A JP2021535119A (ja) 2021-12-16
JP2021535119A5 true JP2021535119A5 (cg-RX-API-DMAC7.html) 2024-03-13

Family

ID=63668212

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021509906A Pending JP2021535119A (ja) 2018-08-22 2019-08-22 アシル化カルシトニン模倣体
JP2024193478A Pending JP2025023996A (ja) 2018-08-22 2024-11-05 アシル化カルシトニン模倣体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024193478A Pending JP2025023996A (ja) 2018-08-22 2024-11-05 アシル化カルシトニン模倣体

Country Status (18)

Country Link
US (1) US20220380432A1 (cg-RX-API-DMAC7.html)
EP (1) EP3840774A1 (cg-RX-API-DMAC7.html)
JP (2) JP2021535119A (cg-RX-API-DMAC7.html)
KR (2) KR20250143876A (cg-RX-API-DMAC7.html)
CN (5) CN121226531A (cg-RX-API-DMAC7.html)
AU (2) AU2019323697B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021003088A2 (cg-RX-API-DMAC7.html)
CA (1) CA3110033A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000427A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021002071A2 (cg-RX-API-DMAC7.html)
EA (1) EA202190477A1 (cg-RX-API-DMAC7.html)
GB (1) GB201813678D0 (cg-RX-API-DMAC7.html)
IL (1) IL280885B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021002072A (cg-RX-API-DMAC7.html)
PE (1) PE20211785A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550331A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020039051A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202100869B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
AR124295A1 (es) 2020-12-18 2023-03-15 Lilly Co Eli Agonistas duales del receptor de amilina y calcitonina y usos de los mismos
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
CN118684757A (zh) * 2023-03-24 2024-09-24 成都奥达生物科技有限公司 一种长效降钙素类似物

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
US5102666A (en) 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU742270B2 (en) 1997-04-16 2001-12-20 Enteris Biopharma, Inc. Direct expression of peptides into culture media
JP2002531518A (ja) 1998-12-04 2002-09-24 プロヴァリス・ユーケー・リミテッド インスリン含有医薬組成物
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US6780846B1 (en) 1999-09-27 2004-08-24 Elan Corporation, Plc Membrane translocating peptide drug delivery system
GB2368792A (en) 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
EP1608347B1 (en) 2003-03-28 2014-08-13 Sigmoid Pharma Limited Solid oral dosage form containing seamless microcapsules
GB0308732D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
JP4829783B2 (ja) * 2003-06-24 2011-12-07 バイオコン・リミテッド カルシトニン薬−オリゴマーコンジュゲートの混合物および疼痛治療における使用方法
PT2316473E (pt) 2003-07-23 2013-09-20 Novartis Ag Utilização de calcitonina na osteoartrite
AU2004317954A1 (en) 2003-09-17 2005-10-13 Chiasma, Inc. Compositions capable of facilitating penetration across a biological barrier
JP2008506750A (ja) 2004-07-22 2008-03-06 ティオマトリックス・フォルシュンクス・ウント・べラートゥンクス・ゲーエムベーハー チオール基を含む化合物の排出ポンプ抑制剤としての使用
US7445911B2 (en) 2004-11-24 2008-11-04 Unigene Laboratories Inc. Enzymatic reactions in the presence of keto acids
EP1907561B1 (en) 2005-06-24 2013-08-28 Unigene Laboratories, Inc. Cell lines for expressing enzyme useful in the preparation of amidated products
EP2722054B1 (en) 2005-09-06 2018-03-21 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
PT1834635E (pt) 2006-03-13 2011-10-13 Advanced In Vitro Cell Technologies S L Sistemas estáveis de nanocápsula para a administração de moléculas activas
BRPI0710503A2 (pt) 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
EP2405934B1 (en) * 2009-03-12 2014-03-26 Nordic Bioscience A/S Treatment of diabetes and metabolic syndrome
WO2011051312A1 (en) * 2009-10-30 2011-05-05 Novo Nordisk A/S Derivatives of cgrp
JP6231386B2 (ja) * 2010-11-09 2017-11-15 ノヴォ ノルディスク アー/エス リンカーを有する二重アシル化されたglp−1誘導体
SI3095484T1 (en) * 2011-11-02 2018-08-31 Keybioscience Ag Calcitonin mimetics for the treatment of diseases and disorders
US9533022B2 (en) * 2011-11-02 2017-01-03 KeyBioscience A/S Peptide analogs for treating diseases and disorders
CA2854175A1 (en) * 2011-11-02 2013-05-10 Keybioscience Ag Peptide analogs for treating diseases and disorders
BR112016010643A2 (pt) * 2013-11-14 2017-12-05 Keybioscience Ag peptídeo
GB201500263D0 (en) * 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
EP3359181A1 (en) * 2015-10-07 2018-08-15 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide drugs
KR102444366B1 (ko) * 2016-06-03 2022-09-19 케모센트릭스, 인크. 간 섬유화 치료 방법

Similar Documents

Publication Publication Date Title
JP2012506402A5 (cg-RX-API-DMAC7.html)
CN114901683B (zh) 胰岛素衍生物
JP2025093970A (ja) インクレチン類似体およびその使用
JP2012529463A5 (cg-RX-API-DMAC7.html)
AU2014350328B2 (en) Calcitonin mimetics for treating diseases and disorders
JP2023510218A (ja) 長時間作用型glp-1化合物
ES3023833T3 (en) Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
KR20130018965A (ko) 목적 펩타이드의 혈장내 반감기 연장 작용을 가진 펩타이드
AU2019323697B2 (en) Acylated calcitonin mimetics
JP2017537894A (ja) Glp−1rおよびglp−2r二重アゴニスト活性を有する組成物及びペプチド
JP2008533105A5 (cg-RX-API-DMAC7.html)
JP2006528982A (ja) ペプチドyyおよびpyy作用薬の送達用組成物
JP2022551282A5 (cg-RX-API-DMAC7.html)
JP2023505441A5 (cg-RX-API-DMAC7.html)
JP2025172864A5 (cg-RX-API-DMAC7.html)
JP2023502005A5 (cg-RX-API-DMAC7.html)
JP2020521784A5 (cg-RX-API-DMAC7.html)
JP2025517672A5 (cg-RX-API-DMAC7.html)
RU2025104355A (ru) Соединение двойного агониста длительного действия
RU2024100299A (ru) Лечение ожирения и связанных с ожирением нарушений
JP2025513345A5 (cg-RX-API-DMAC7.html)
CN117015393A (zh) 包含鞭毛蛋白融合蛋白的用于预防或治疗非酒精性脂肪肝病或代谢综合征的组合物
HK40109784A (en) Insulin derivative
CN121002051A (zh) 肠促胰素类似物及其制备方法和应用
EA050377B1 (ru) Ацилированные миметики кальцитонина